Respiratory allergies are a common problem in pregnancy. Asthma in pregnancy is characterized by greater clinical and functional instability, which makes disease control very difficult in several cases. Approximately one third of asthmatic patients undergoes exacerbation during pregnancy, and a mild to moderate asthma may progress to more severe stages. Drug therapies for respiratory allergies must necessarily take into account possible risks to the fetus, on whom - at the same time - failure to control asthma may have negative consequences. It was noted that the incidence of teratogenesis induced by asthma medications is rare. However, it is good practice to use extreme caution when administering medicines, particularly in the first quarter. The decision whether to use a drug which is known potentially harmful to the fetus must be taken also on the basis of an assessment of the benefits that would result from this practice, and of the potential consequences if these drugs were not used. The aim of this paper is to evaluate the safety and indications of the different treatment options available, both for rhinitis and asthma.
|Translated title of the contribution||Treatment of respiratory allergies in pregnancy. Safety of use to the fetus|
|Number of pages||8|
|Journal||Italian Journal of Allergy and Clinical Immunology|
|State||Published - Jun 1 2010|
ASJC Scopus subject areas
- Immunology and Allergy